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Abstract Resistance to antiretroviral agents is a signifi-
cant concern in the clinical management of HIV-infected
individuals, particularly in areas of the world where
treatment options are limited. In this study, we aimed to
identify HIV drug-resistance-associated mutations in 40
drug-naı¨ve patients and 62 patients under antiretroviral
therapy (ART) referred to the Shiraz HIV/AIDS Research
Center – the first such data available for the south of Iran.
HIV reverse transcriptase and protease genes were
amplified and sequenced to determine subtypes and
antiretroviral- resistance-associated mutations (RAMs).
Subtype CRF35-AD recombinant was the most prevalent
in all patients (98 of 102, 96 %), followed by subtype A1,
and subtype B (one each, 2 %). Among the 40 ART-naı¨ve
patients, two mutations associated with nucleoside reverse
transcriptase inhibitor (NRTI) resistance (two with Y115F
and T215I) and three associated with non-nucleoside
reverse transcriptase inhibitor (NNRTI) resistance (two
with G190S and Y181C, four with V179T) were found.
Among ART-experienced patients, four mutations asso-
ciated with resistance to NRTI, four with NNRTI, and
five with protease inhibitors (PI) were found. Twenty
patients with high levels of resistance were already on
second-line therapy. We document for the first time in
this region of Iran high levels of ART resistance to
multiple drugs. Our findings call for more vigilant sys-
tematic ART resistance surveillance, increased resistance
testing, careful management of patients with existing
regimens, and strong advocacy for expansion of available
drugs in Iran.
Introduction
Although not curative, combinational antiretroviral therapy
(ART) has proven to be effective in controlling HIV
replication. Currently, there are six different classes of
regimens to treat HIV, the three most common in Iran
being nucleoside and nucleotide analogue reverse tran-
scriptase inhibitors (NRTI), non-nucleoside reverse tran-
scriptase inhibitors (NNRTI), and protease inhibitors (PI)
[1]. ART generally includes two NRTI and one NNRTI.
For HIV-positive patients in Shiraz, zidovudine (AZT),
lamivudine (3TC) and efavirenz (EFV) are used as the first-
line therapy. When treatment fails, second-line therapy
usually includes 3TC, tenofovir (TDF), and Kaletra (lopi-
navir/ritonavir).
Regardless of the significant achievements in terms of
viral suppression, resistance to ART agents is a concern, as
it can lead to treatment failure [2]. ART resistance results
from mutations appearing across the genome, targeting
viral proteins [1]. As many as 50 % of patients in the US
show resistance to at least one available antiretroviral drug
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[3]. The US, however, has multiple drug classes and agents
to use when treatment fails. In much of the world, few
options are present beyond a first and second line. Fewer
still are currently available for wide use.
HIV genotype diversity is a result of high mutation rates
of the reverse transcriptase gene combined with a high viral
turnover rate under the selective pressure of ART and the
immune system [4]. Some studies link differences between
subtypes to the rate of HIV disease progression [5], while
other studies have not found such differences [6]. HIV
subtypes might be important for the development of
resistance to ART agents. There are also studies on the
effect of subtype on the outcome of ART in patients, with
some reporting differences between B and non-B subtype
viruses in the development of drug resistance [7]. Other
studies report no differences on the outcome of treatment
by subtype [8].
Primary drug resistance is a major concern, as an ART-
naı¨ve patient may carry resistant virus without any prior
treatment [9]. Indeed, 7-17 % of naı¨ve patients have ART
resistance in high-income countries in North America and
Western Europe, whereas in middle- and low-income
countries, an estimated 7 % have ART resistance [10]. The
prevalence of primary resistance in counseling and
behavioral centers in Tehran and nine provinces of Iran has
been reported to be 5-15 % [11–13], with CRF35_AD as
the predominant subtype [12, 14]. However, no data on
primary or secondary ART resistance have been reported
from the south of Iran. We therefore present the results of
the first study to determine ART-resistance-associated
mutations among newly diagnosed ART-naı¨ve and ART-
experienced patients in Shiraz, southern Iran’s most pop-
ulous city.
Materials and methods
Study participants
For the purpose of this cross-sectional study, 108 HIV-
positive patients consecutively seen at the Counseling
Behavior Modification Center in Shiraz from April 2013 to
February 2014 were recruited. Of these, 40 were newly
diagnosed ART-naı¨ve, and 68 had been under treatment for
at least one year, using a regimen that included two NRTIs
with one NNRTI (NNRTI-based regimen) for 48, and two
NRTI with combination of PI (PI-based regimen) for the
remaining 20. Informed consent was obtained from each
patient.
The study protocol was approved by the Committee of
Medical Research Ethics in Golestan and Shiraz University
of Medical Sciences.
RNA isolation, amplification, and genotyping
Blood samples were obtained in sterile EDTA-containing
tubes, and plasma was separated and stored at -70 C. RNA
was extracted from plasma according to the manufacturer’s
protocol (Roche Total RNA and DNA Extraction Kit).
cDNA synthesis was performed at 50 C for 30 minutes
using a one-step kit as indicated by the manufacturer
(Invitrogen).
Two parts of the HIV pol gene were amplified by nested
RT-PCR following standard procedures. Briefly, the HIV
protease gene was amplified using the following reaction
mixture: 5 lL of cDNA, 4.5 lL of 10X PCR buffer, 1 lL
of 10 mM dNTP, 0.3 lL of 5 U pfu polymerase, 6 lL of
100 mM MgCl2, 0.1 lL of each PCR primer (10 pM) and
37 lL of DEPC-treated water. The final amplified region
covered the HIV protease gene from codon 9 to codon 99.
The following primer pairs were used: outer sense primer
(SEQ ID NO -1), 5’ CAG AGC CAA CAG CCC CAC
CAG3’; outer antisense primer (SEQ ID NO -2), 5’ ATC
AGG ATG GAG TTC ATA ACC CAT CCA 3’; nested
sense primer (SEQ ID NO -3), 5’ CCT CAR ATC ACT
CTT TGG CAA CG 3’; nested antisense primer (SEQ ID
NO -4), 5’ CTG GTA CAG TYT CAA TAG GRC TAA T
[15]. Annealing was done at 57 C, extension at 72 C and
denaturation at 94 C. Each step of a cycle was carried out
for 1 minute. The outer PCR consisted of 40 cycles, and
the nested round consisted of 35 cycles. A final extension
step at 72 C was carried out for 2 minutes.
The RT gene was amplified using the following reaction
mixture: 5 lL of cDNA, 4.5 lL of 10X PCR buffer,
0.25 lL of 40 mM dNTP, 0.3 lL of 5 U pfu polymerase,
3 lL of 100 mM MgCl2, 0.1 lL of each PCR primer at
10 pM and 39 lL of DEPC-treated water. The amplicon
was a 665-bp region encoding amino acids 17 to 237 of the
RT gene, and the following primer pairs were used: outer
sense primer (RT-1), 5’ GTT GAC TCA GAT TGG TTG
CAC 3’; outer antisense primer (RT -2), 5’ GTA TGT CAT
TGA CAG TCC AGC 3’; nested sense primer (RT -4), 5’
GGA TGG CCC AAA AGT TAA AC 3’; nested antisense
primer (RT -3), 5’ TAT CAG GAT GGA GTT CAT AAC
[16]. The PCR conditions were as follows: 94 C for 5 min
followed by 35 cycles of 94 C for 30 seconds (denatura-
tion), 55 C for 30 seconds (annealing), and 72 C for
1 minute (extension). A final extension step at 72 C was
carried out for 4 minutes.
Both PCR products were visualized on a 2 % agarose
gel with ethidium bromide staining. The PCR products
were decontaminated using a gel purification kit (Bioneer)
and sequenced on both strands in an automated DNA
sequencer (ABI PRISM 3730 version 3.0, Applied
Biosystems, Foster City, CA).
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Subtype and drug resistance interpretation
and phylogenetic tree
Sequences were corrected using Bioedit software (ver.
7.0.5.3). The protease and RT sequences were analyzed
using the Stanford University HIV Drug Resistance
mutations databases (version 4.2.6 [http://hivdb.stanford.
edu]) for determination of drug resistance in patients [17].
Phylogenetic analysis was done by the neighbor-joining
method with 1000 bootstrap replicates and Kimura’s two-
parameter correction. The phylogenetic tree was con-
structed using Molecular Evolutionary Genetics Analysis
(MEGA) software, version 4 [18].
The pol nucleotide sequences reported in this study have
been deposited in the GenBank database under accession
numbers KX086583-KX086683.
Results
A total of 108 HIV-positive patients were initially included
in this study, for whom 102 samples were suitable for
sequencing. The characteristics of these 102 participants
are shown in Table 1. Of the 40 ART-naı¨ve patients, 35 %
were female, the mean age was 37 years (SD ±7), and the
mean CD4 count was 391 (SD ±163). Reported trans-
mission routes were 45 % intravenous drug use, 30 % had
an HIV-infected husband, 15 % had multiple sex partners,
5 % were reported to have been infected through blood
products, and 5 % had no risk reported. Among the 62
ART-experienced patients, 42 % were female, the mean
age was 41 years (SD ±6), and the mean CD4 count was
202 (SD ±107). Reported transmission routes were 48 %
intravenous drug users, 26 % HIV-infected husband, 16 %
multiple sex partners, 7 % blood products, and 3 %
tattooing.
Most patients (48, 77 %) on ART used combined doses
of AZT, 3TC, and EFV as the first-line therapy for at least
one year. The remainder were using 3TC, TDF, and Kaletra
as second-line therapy.
Subtype CRF35-AD recombinant was the most preva-
lent in all patients (98 of 102 or 96 %), followed by sub-
type A1, and subtype B (each 2 %).
Several mutations associated with NRTI and NNRTI
resistance were detected in ART-naı¨ve patients (Table 2).
Detected ART-resistance-associated mutations related to
NRTI were Y115F (two, or 5 % of the patients) and T215I
(5 % of the patients). Y115F reduces abacavir (ABC)
susceptibility *3-fold but has little phenotypic effect on
tenofovir (TDF), and T215I does not decrease NRTI sus-
ceptibility but arises from patients primarily infected with
strains containing T215Y/F. Y181I (two, or 5 % of the
patients), G190S (5 % of the patients), and V179T (four,
10 % of the patients) were mutations related to NNRTI. By
patients, accounting for multiple mutations in individuals,
NRTI resistance was present in 5 %, and NNRTI in 10 %.
No major PI drug RAMs were seen among ART-naı¨ve
individuals. In the ART-naı¨ve patients, only two (5 % of
Table 1 Characteristics of
HIV-positive patients according
to antiretroviral treatment
(ART) status, Shiraz, Iran, 2014
(N = 102)
Characteristic ART-naı¨ve ART-experienced
N (%) or mean (SD) N (%) or mean (SD)
Total 40 (100) 62 (100)
Sex:
Male 26 (65) 36 (58)
Female 14 (35) 26 (42)
Mean age (years) 37 ± 7 41 ± 6
Mean CD4 count 391 ± 163 202 ± 107
Reported transmission route:
Intravenous drug use 18 (45) 30 (48)
HIV-infected husband 12 (30) 16 (26)
Multiple sex partners 6 (15) 10 (16)
Blood products 2 (5) 4 (7)
Tattooing - 2 (3)
Unreported/unknown 2(5) -
Years of diagnosis 2011-2013 2007-2012
Years since start of treatment
1 NA 32 (52)
2 10 (16)
3-5 16 (25)
5? 4 (7)
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the patients) individuals had multiple mutations, namely
Y181I, Y115F, and T215I.
The genotyping resistance interpretation algorithm
indicated resistance to AZT (two, or 5 % of the patients),
D4T (5 % of the patients), DDI (5 % of the patients) for
NRTI, and resistance to EFV (four, or 10 % of the
patients), NVP (10 % of the patients), ETR (10 % of the
patients), and PRV (10 % of the patients) for NNRTI
(Table 3).
In the ART-experienced patients, major mutations
associated with resistance to NNRTI were K103N (six, or
10 % of the patients), P225H (two, or 3 % of the patients),
Table 2 Antiretroviral drug RAMs detected in HIV-positive patients in Shiraz, Iran in 2014 according to treatment history
Mutations detected in ART-naı¨ve patients (n = 40) Mutations detected in ART-experienced patients (n = 62)
NRTI NNRTI PI NRTI NNRTI PI
2 (Y115F) 2 (G190S) - 6 (V75M) 6 (K103N) 6 (M46L/I)
2 (T215I) 2 (Y181I) - 6 (M184V/I) 2 (P225H) 2 (V82C)
- 4 (V179T) - 2 (K65N) 2 (V179T) 2 (V82A)
- - - 2 (K219Q) 2 (Y181C) 2 (I54V)
- - - - - 2 (L90M)
NRTI, nucleoside reverse transcriptase inhibitor; NNRT, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor
Table 3 Levels of antiretroviral drug resistance in HIV-positive patients in Shiraz, Iran in 2014 (N = 102) according to treatment history
ART-experienced patients (n = 62) ART-naı¨ve patients (n = 40)
First-line therapy (n = 42) (2NRTI?1NNRTI) Second-line therapy (n = 20) (2NRTI?1PI) No therapy
Level of resistance Level of resistance Level of resistance
NRTI High
n (%)
Intermediate
n (%)
Low
n (%)
High
n (%)
Intermediate
n (%)
Low
n (%)
High
n (%)
Intermediate
n (%)
Low
n (%)
3TC - - 2 (5) 6 (30) - - - - -
ABC - - 2 (5) - - 6 (30) - 2 (5) -
AZT - - - - - 2 (10) - - 2 (5)
D4T - - - 4 (20) - 2 (10) - - 2 (5)
DDI 2 (5) - 2 (5) - 4 (20) 6 (30) - - 2 (5)
FTC 2 (5) 2 (5) - 6 (30) - 2 (10) - - -
TDF - - 2 (5) - - - - - 2 (5)
NNRTI
EFV 4 (10) 2 (5) - 2 (10) - - 2 (5) 2 (5) -
ETR - - - - 2 (10) - 2 (5) - 2 (5)
NVP 4 (10) - 2 (5) 2 (10) - - 4 (10) - -
PRV - - - - 2 (10) - 2 (5) - 2 (5)
PI
ATV - - 2 (5) - 4 (20) 4 (20) - - -
DRV - - - - - - - - -
FPV - - 2 (5) - 4 (20) 4 (20) - - -
IDV - - 2 (5) - 4 (20) 4 (20) - - -
LPV - - 2 (5) - 2 (10) 6 (30) - - -
NFV - - 2 (5) 2 (10) 2 (10) 4 (20) - - -
SQV - - 2 (5) - 4 (20) - - - -
TPV - - 2 (5) - - 2 (10) - - -
NRTI, nucleoside reverse transcriptase inhibitor; NNRT, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor
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V179T (3 % of the patients) and Y181C (3 % of the
patients) (Table 2). Detected NRTI mutations were V75M
and M184I/V (six, or 10 % patients each), K219Q and
K65N (two each, or 3 % of the patients). Mutations asso-
ciated with PI among ART-experienced patients were
M46L/I (six, or 10 % of the patients), and I54V, L90M,
V82C, and V82A (two each, or 3 % of the patients). All
patients with PI mutations had PI in their current or past
regimens. In addition, minor PI RAMs were L10I/V (eight,
or 13 % of the patients) and A71T (four, or 6 % of the
patients). Among the 62 ART-experienced patients, 26
(42 % of the patients) had at least one drug RAM, twenty
(32 % of the patients) had RAMs to one drug class, six
(10 % of the patients) had resistance to two drug classes,
and two (3 % of the patients) had RAMs to all three drug
classes assessed. In these patients, resistance to NRTI,
NNRTI, and PI were 26 %, 13 %, and 16 %, respectively.
The genotyping resistance interpretation algorithm indi-
cated 23 % resistance to DDI, 10 % resistance to D4T, and
10 % resistance to 3TC in the NRTI group and 13 %
resistance was seen to EFV and NVP. Of the ART-expe-
rienced patients, ten (16 % of the patients) had multiple
mutations.
In addition to RAMs, there were other polymorphisms in
our sequences that had no association with drug resistance.
For example, V179I, V60I, K122E, L234P, H235P in the
RT region and L89M, E35D, M36I, and H69K in the PR
region are common polymorphisms in our study that are
not associated with decreased NNRTI and PI susceptibility,
respectively.
Discussion
Tracking primary and secondary ART resistance provides
important patient-care and public-health information,
which is particularly critical in settings with few treatment
options and lines of therapy. We present the first study of
ART resistance in the south of Iran, in Shiraz, and found
substantial transmitted resistance and resistance among
patients on first- and second-line treatment. Levels reported
in this region are comparable to elsewhere in Iran [11, 19].
We also confirm that the most common subtype was sub-
type CRF35-AD as elsewhere in the country
[12, 14, 20–22]. Any resistance is a potential threat because
inadequate suppression of HIV replication by ART affects
individual patient care as well as onward transmission of
infection.
Transmission of resistant viruses is a particular concern
when considering initiation of ART in new patients. In
ART-naı¨ve patients, we found 10 % resistance to NNRTI
and 5 % to NRTI, a finding consistent with previous
studies in Iran that have calculated primary resistance at 5
to 15 % [11, 13, 23]. When the frequency of transmitted
drug resistance is estimated at 8 %–10 %, drug-resistance
testing before commencement of ART in untreated patients
is cost-effective [24]. In the ART-naı¨ve patients, we found
two NRTI RAMs and three NNRTI RAMs. Mutation
V179T was reported in four individuals and this might
contribute to reduced ETR susceptibility in combination
with other mutations. Mutations Y181I and G190S were
similar to the profile of mutations found by Smith et al.
[25]. Our rate of primary resistance in ART-naı¨ve partici-
pants was lower than among patients in the United States,
Europe, Australia, and Japan, where it was estimated to be
between 10 % and 17 % by WHO [26]. Fortunately, for the
present, we detected no major PI drug RAMs among ART-
naı¨ve patients. This phenomenon is probably caused by the
higher genetic barrier for PI resistance and not having PI in
the first-line regimen in Iran. PI-associated RAMs in our
ART-experienced patients was 16 %, similar to other Ira-
nian studies [11, 19].
Our data allowed us to identify mutations associated
with ART resistance among those undergoing both first-
and second-line treatment. The K103N mutation was the
most common NNRTI mutation detected in ART-experi-
enced patients. Recently, K103N was shown to be the most
important NNRTI RAM due to the 20- to 50-fold increase
in resistance against each of the available NNRTIs [27].
The proportion of patients with a NNRTI-resistance-asso-
ciated mutations is higher in treated patients than in drug-
naı¨ve patients, probably due to poor ART adherence and
pharmacologic pressure [28]. We found highest resistance
for EFV and NVP, both of which are used in first-line
therapy. Resistance to 3TC, 13 % here, is lower than in
previous studies that reported 53 %, 60 % and 25 % in Iran
[11, 19, 28]. Use of ART increases the chance of resistance
in patients with incomplete viral suppression, and it may
cause treatment failure [29]. The highest resistance rate
(26 %) in treatment-experienced participants was seen
against NRTI, which is similar to the results reported by
Hamkar et al. [19]. The most prevalent mutation was
V75M, which is related to resistance to stavudine (D4T)
and didanosine (DDI). Another common mutation related
to NRTI was M184I/V in six patients. This mutation can
cause high-level resistance to 3TC and emtricitabine (FTC)
and low-level resistance to abacavir (ABC) and DDI. A
mutation in position 184 was the most prevalent mutation
associated with resistance to NRTI in other studies [23].
The high level of resistance to 3TC is the result of the
M184V/I mutation. When only 3TC is used as a drug
regimen, resistant strains become the main strain in a few
weeks [30], and M184V is the first mutation to appear
when 3TC is used in an ART regimen [1]. Among patients
receiving ART, resistance to 3TC was more common for
PI-based regimens, probably as a result of second-line
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therapy in these patients. More investigation is needed to
confirm this. Although FTC use was not reported, accu-
mulation of NRTI mutations in patients with PI-based
regimens on 3TC resulted in frequent high-level (30 %) or
low-level (10 %) cross-resistance to FTC.
Among twenty patients on second-line therapy, two
patients had a combination of RAMs to all three drug
classes (NRTI, K219Q; NNRTI, K103N and Y181C; PI,
I54V and V82A), probably as a result of non-adherent to
drugs in these patients. On the other hand, there were six
cases with combination of RAMs to NRTI and NNRTI.
The profile of mutations in the protease region was
different from those in other Iranian studies. For example,
RAMs to PI such as A71T, L10V, L10F, Q58F, I50V, and
I84V have been reported by Hamkar et al. and Baesi et al.
[11, 19]. PI RAMs were seen in 16 % of patients, and as
expected, they were less frequent than reverse transcrip-
tase inhibitor mutations because of a natural genetic
protease barrier to mutation [28]. Although patients on
first-line therapy did not receive PI, low-level resistance
associated with PI mutations was detected in this group.
We think this might be due to drug-selective pressure or
transmitted drug resistance. Consistent with a previous
report, maximum and minimum resistance was reported
against nelfinavir (NFV), saquinavir (SQV), and darunavir
(DRV) [11].
We recognize the limitations of our study. First, the
overall sample size is small. Second, the study population
was recruited from those visiting clinics. We do not have
information on the level of primary and secondary resis-
tance in the community at large.
Conclusion
In much of the world, genotyping is widely used in clinical
settings, with evidence from several trials supporting their
efficacy in improving patient management [31]. Most of
the time in Iran, treatment is started without genotyping
testing. With due attention to the presence of primary
resistance in drug-naı¨ve patients as shown in our study, the
importance of genotyping assay for better clinical outcome
and inhibition of resistance in these patients should be
evident.
Our first study on drug resistance among HIV-positive
patients in Shiraz emphasizes the need for resistance test-
ing before initiation of therapy in drug-naı¨ve patients in
order to select the best therapeutic approaches, and before
switching to second-line therapy for other patients. In
addition, we recommend a more systematic surveillance for
resistance patterns and further studies to assess major
mutations associated with antiretroviral drug resistance in
Iranian patients. Finally, given the current situation and the
likelihood of developing and transmitting resistance, there
needs to be advocacy for increased availability and
affordability of newer ART options.
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